Molecular Adsorbent Recirculating System (MARS®) in Hypoxic Hepatitis
Launched by MEDICAL UNIVERSITY OF VIENNA · Sep 19, 2012
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • presence of severe hypoxic hepatitis with aminotransferase levels \> 40 times the upper limit of normal
- • duration of hypoxic hepatitis more than 12 hours
- • age \>/= 18 years
- Exclusion Criteria:
- • age \< 18 years
- • pregnancy
- • DNR - order
- • liver cirrhosis
- • Cardiopulmonary resuscitation with unknown neurological outcome and/or hypoxic brain damage
- • Expected survival of less than 24 hours
Trial Officials
Valentin Fuhrmann, Prof
Principal Investigator
Medical University Vienna
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Vienna, , Austria
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
